Relationship of sodium/iodide symporter expression with I131 whole body scan uptake between primary and metastatic lymph node papillary thyroid carcinomas
- PMID: 17318019
- DOI: 10.1007/BF03347392
Relationship of sodium/iodide symporter expression with I131 whole body scan uptake between primary and metastatic lymph node papillary thyroid carcinomas
Abstract
The aim of the present study was to evaluate total and membranous Na+/I- symporter (NIS) expressions in papillary thyroid carcinoma (PTC) tissue, correlation of NIS expression between primary and metastatic lymph node (LN) PTC tissues, and relationship of NIS expression with I131 whole body scan (WBS) uptake between primary and metastatic LN PTC tissues by analyzing 17 pairs of primary and metastatic LN PTC tissues. Staining positivity was calculated, and staining intensity was graded as negative (0), weak (1+), moderate (2+) and strong (3+). In primary PTC tissues, positivities and intensities of normal cells were higher than those of carcinoma cells but had no correlation with those in matched metastatic LN PTC tissues. In classic type, positivities, intensities and membranous intensities (mIS) were correlated between primary and matched metastatic LN PTC tissues. In patients aged younger than 45 yr, positivities and intensities in primary PTC tissues had correlation with those in matched metastatic LN PTC tissues. Positivities, intensities, mIS and pathological subtype of carcinoma cells in primary PTC tissues were not correlated with age, tumor size, TNM stage, MACIS score and thyroglobulin (Tg) levels at the time of I131 WBS. Sensitivity, specificity, as well as positive and negative predicted values of mIS in patients with I131 WBS uptake were 69.2, 75, 90 and 42.9% in primary PTC tissues, and 92.3, 100, 100 and 80% in metastatic LN PTC tissues. The results of mIS taken either as positive or negative were correlated with those of I131 WBS after controlling for age. Our results demonstrate that PTC tissues have altered total and membranous NIS expressions, suggesting that NIS expression in primary PTC tissues may predict NIS expression and I131 WBS uptake in matched metastatic LN PTC tissues.
Similar articles
-
Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma.Eur J Nucl Med. 2001 May;28(5):639-45. Eur J Nucl Med. 2001. PMID: 11383871
-
Expression of sodium-iodide symporter and TSH receptor in subclinical metastatic lymph nodes of papillary thyroid microcarcinoma.Ann Surg Oncol. 2012 Mar;19(3):990-5. doi: 10.1245/s10434-011-2047-y. Epub 2011 Aug 31. Ann Surg Oncol. 2012. PMID: 21879263
-
Expressions of human sodium iodide symporter mRNA in primary and metastatic papillary thyroid carcinomas.Thyroid. 2000 Mar;10(3):211-7. doi: 10.1089/thy.2000.10.211. Thyroid. 2000. PMID: 10779135
-
Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism.Eur J Endocrinol. 1999 Nov;141(5):443-57. doi: 10.1530/eje.0.1410443. Eur J Endocrinol. 1999. PMID: 10576759 Review.
-
The importance of sodium/iodide symporter (NIS) for thyroid cancer management.Arq Bras Endocrinol Metabol. 2007 Jul;51(5):672-82. doi: 10.1590/s0004-27302007000500004. Arq Bras Endocrinol Metabol. 2007. PMID: 17891230 Review.
Cited by
-
Visualization of gene expression in the live subject using the Na/I symporter as a reporter gene: applications in biotherapy.Br J Pharmacol. 2010 Feb;159(4):761-71. doi: 10.1111/j.1476-5381.2009.00412.x. Epub 2009 Oct 8. Br J Pharmacol. 2010. PMID: 19814733 Free PMC article. Review.
-
Seaweed and Iodine Intakes and SLC5A5 rs77277498 in Relation to Thyroid Cancer.Endocrinol Metab (Seoul). 2022 Jun;37(3):513-523. doi: 10.3803/EnM.2021.1306. Epub 2022 May 24. Endocrinol Metab (Seoul). 2022. PMID: 35607818 Free PMC article.
-
A novel microfluidic device capable of maintaining functional thyroid carcinoma specimens ex vivo provides a new drug screening platform.BMC Cancer. 2019 Mar 22;19(1):259. doi: 10.1186/s12885-019-5465-z. BMC Cancer. 2019. PMID: 30902086 Free PMC article.
-
Iodine avidity in papillary and poorly differentiated thyroid cancer is predicted by immunohistochemical and molecular work-up.Eur Thyroid J. 2023 Jul 28;12(4):e230099. doi: 10.1530/ETJ-23-0099. Eur Thyroid J. 2023. PMID: 37352166 Free PMC article.
-
Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.Endocrine. 2015 Aug;49(3):726-34. doi: 10.1007/s12020-014-0481-x. Epub 2014 Nov 21. Endocrine. 2015. PMID: 25414068
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous